A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin-tcgd) (SkybriGHt)
A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin-tcgd) (SkybriGHt)
-
Clinical Trial Information
Trial Contact: Tilme, Linda; Beltran, Yajira
Trial Phone: 321.843.5278 ; 321.841.7619
-
IRB No: 23.093.05
Protocol Abbrev: ASND0037
Principal Investigator: Joshua H Yang, MD
Phase: Drug: Phase III
Age Group: Pediatric
ClinicalTrials.gov ID: NCT05820672
-
Objective
The goal of this study is to generate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
-
Key Eligibility
Inclusion Criteria:
Patients who are on treatment with SKYTROFA (lonapegsomatropin)
Patients being clinically managed in USA
Patients with an appropriate written informed consent/assent as applicable for the age of the patient
